Literature DB >> 2971785

Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease.

S M de la Monte1, J P Vonsattel, E P Richardson.   

Abstract

We performed morphometric analysis of five standardized coronal brain slices at anterior frontal (AF), caudate-putamen-accumbens (CAP), globus pallidus (GP), lateral geniculate nucleus (LGN), and parieto-occipital fissure (OCP) levels in 30 patients with Huntington's disease (HD) and 13 controls. Associated with the 30% mean reduction in brain weight in HD patients (p less than 0.001) were significantly smaller overall cross-sectional areas of brain at all five levels studied, with striking losses in cerebral cortex (21-29%), white matter (29-34%), caudate (57%), putamen (64%), and thalamus (28%) (all p less than 0.005). In addition, the ventricular system was dilated up to 2.5 times normal at CAP, GP, and LGN levels, 9.5 times normal at the OCP level, and 13 times normal at the AF level. Higher grades of severity of HD had greater reductions in the cross-sectional area of the caudate, putamen, thalamus, and cerebral cortex (p less than 0.005-0.001), and larger ventricles (p = 0.08) compared to lower (less severe) grades of HD. The findings confirm and quantitate the severe atrophy of the neostriatum, in addition to demonstrating a severe loss of cerebral cortex and subcortical white matter in HD. The global atrophy of cerebral cortex and white matter observed in all degrees of HD may account for the cognitive and neuropsychiatric impairments which often precede the onset of chorea.

Entities:  

Mesh:

Year:  1988        PMID: 2971785     DOI: 10.1097/00005072-198809000-00003

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  107 in total

1.  Basal ganglia alterations and brain atrophy in Huntington's disease depicted by transcranial real time sonography.

Authors:  T Postert; B Lack; W Kuhn; M Jergas; J Andrich; B Braun; H Przuntek; R Sprengelmeyer; M Agelink; T Büttner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-10       Impact factor: 10.154

2.  From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease.

Authors:  S W Davies; M Turmaine; B A Cozens; A S Raza; A Mahal; L Mangiarini; G P Bates
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 3.  Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease.

Authors:  J H Cha; A S Frey; S A Alsdorf; J A Kerner; C M Kosinski; L Mangiarini; J B Penney; S W Davies; G P Bates; A B Young
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 4.  Transgenic models of Huntington's disease.

Authors:  K Sathasivam; C Hobbs; L Mangiarini; A Mahal; M Turmaine; P Doherty; S W Davies; G P Bates
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

5.  Cognitive procedural learning in patients with fronto-striatal lesions.

Authors:  Klaus Schmidtke; Hendrik Manner; Robert Kaufmann; Heike Schmolck
Journal:  Learn Mem       Date:  2002 Nov-Dec       Impact factor: 2.460

6.  Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.

Authors:  Andrew T N Tebbenkamp; Cameron Green; Guilian Xu; Eileen M Denovan-Wright; Aaron C Rising; Susan E Fromholt; Hilda H Brown; Debbie Swing; Ronald J Mandel; Lino Tessarollo; David R Borchelt
Journal:  Hum Mol Genet       Date:  2011-04-22       Impact factor: 6.150

7.  Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

Authors:  Holly B Kordasiewicz; Lisa M Stanek; Edward V Wancewicz; Curt Mazur; Melissa M McAlonis; Kimberly A Pytel; Jonathan W Artates; Andreas Weiss; Seng H Cheng; Lamya S Shihabuddin; Gene Hung; C Frank Bennett; Don W Cleveland
Journal:  Neuron       Date:  2012-06-21       Impact factor: 17.173

8.  Assessment of cortical and striatal involvement in 523 Huntington disease brains.

Authors:  Tiffany C Hadzi; Audrey E Hendricks; Jeanne C Latourelle; Kathryn L Lunetta; L Adrienne Cupples; Tammy Gillis; Jayalakshmi Srinidhi Mysore; James F Gusella; Marcy E MacDonald; Richard H Myers; Jean-Paul Vonsattel
Journal:  Neurology       Date:  2012-10-03       Impact factor: 9.910

9.  Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a conditional mouse model of Huntington's disease.

Authors:  Ana María Estrada-Sánchez; Courtney L Burroughs; Stephen Cavaliere; Scott J Barton; Shirley Chen; X William Yang; George V Rebec
Journal:  J Neurosci       Date:  2015-03-11       Impact factor: 6.167

10.  Enhanced toxicity to the catecholamine tyramine in polyglutamine transfected SH-SY5Y cells.

Authors:  Rebecca R Smith; Edgardo R Dimayuga; Jeffrey N Keller; William F Maragos
Journal:  Neurochem Res       Date:  2005-04       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.